1-methyltryptophan has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, Y; Bhandari, R; Kuhad, A; Kumar, B; Saroj, P; Singh, R; Sodhi, RK | 1 |
| El Osta, B; Floyd, M; Tang, SC | 1 |
2 other study(ies) available for 1-methyltryptophan and Parkinsonian Disorders
| Article | Year |
|---|---|
IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Tryptophan | 2021 |
First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent.
Topics: Female; Humans; Middle Aged; Parkinsonian Disorders; Tryptophan | 2018 |